A renewed Strategic Plan

Uniting stakeholders to share knowledge, foster collaboration, enable solutions and to support the most critical issues, risks and challenges faced by the field

Increasing resources

Mobilizing new funding to support and grow the field of HIV vaccine research and development

Greater collaboration

Promoting more efficient, faster ways for researchers to share successes and failures and avoid duplication of efforts



October 2020 to January 2021

Online content available from 16 October 2020

First online event on 27 October 2020


HVTN 084 – Injectable HIV drug prevents infections

The IAS hosted Global HIV Vaccine Enterprise welcomes interim results showing effectiveness of long-acting injectable PrEP. New results announced today by ViiV healthcare show that injection of long-acting pre-exposure prophylaxis (PrEP) cabotegravir every two months is 89% more effective than a daily Truvada oral pill in a trial of women at increased risk of HIV acquisition.

Upcoming event

Making mAb Accessible webinar

The Global HIV Vaccine Enterprise at the International AIDS Society and IAVI are pleased to invite you to join a webinar to discuss challenges and opportunities on the Access to future monoclonal antibodies for HIV prevention:

“Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – What would it take?’’

Timely topics

In 2012, the Enterprise launched Timely Topics in HIV Vaccines, a strategy series convening experts as rapidly as possible to analyze, address, and respond to unresolved and emerging priority issues in the field. Through an open call for proposals, the Enterprise is working to identify the most important strategic needs of the field and sponsoring think tanks, meetings, forums and other events to tackle these issues.


Sign up to receive the latest news of the Vaccine Enterprise and occasional information related to IAS activities related to vaccine research and development (Please read our Privacy Policy)

WP Twitter Auto Publish Powered By : XYZScripts.com